JP2020536932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536932A5 JP2020536932A5 JP2020520650A JP2020520650A JP2020536932A5 JP 2020536932 A5 JP2020536932 A5 JP 2020536932A5 JP 2020520650 A JP2020520650 A JP 2020520650A JP 2020520650 A JP2020520650 A JP 2020520650A JP 2020536932 A5 JP2020536932 A5 JP 2020536932A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- composition according
- antibody
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023191995A JP2024016220A (ja) | 2017-10-13 | 2023-11-10 | 抗体－薬物コンジュゲートを用いた免疫応答の調節 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572345P | 2017-10-13 | 2017-10-13 | |
| US62/572,345 | 2017-10-13 | ||
| US201762576017P | 2017-10-23 | 2017-10-23 | |
| US62/576,017 | 2017-10-23 | ||
| US201862657511P | 2018-04-13 | 2018-04-13 | |
| US62/657,511 | 2018-04-13 | ||
| PCT/US2018/055388 WO2019075188A1 (en) | 2017-10-13 | 2018-10-11 | MODULATION OF IMMUNE RESPONSE USING CONJUGATES ANTIBODY-MEDICINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191995A Division JP2024016220A (ja) | 2017-10-13 | 2023-11-10 | 抗体－薬物コンジュゲートを用いた免疫応答の調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536932A JP2020536932A (ja) | 2020-12-17 |
| JP2020536932A5 true JP2020536932A5 (enExample) | 2021-11-18 |
Family
ID=66101160
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520650A Pending JP2020536932A (ja) | 2017-10-13 | 2018-10-11 | 抗体−薬物コンジュゲートを用いた免疫応答の調節 |
| JP2023191995A Pending JP2024016220A (ja) | 2017-10-13 | 2023-11-10 | 抗体－薬物コンジュゲートを用いた免疫応答の調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023191995A Pending JP2024016220A (ja) | 2017-10-13 | 2023-11-10 | 抗体－薬物コンジュゲートを用いた免疫応答の調節 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200239585A1 (enExample) |
| EP (1) | EP3694544A4 (enExample) |
| JP (2) | JP2020536932A (enExample) |
| KR (1) | KR20200070317A (enExample) |
| CN (2) | CN111683677A (enExample) |
| AU (1) | AU2018348198A1 (enExample) |
| BR (1) | BR112020007119A2 (enExample) |
| CA (1) | CA3077729A1 (enExample) |
| IL (1) | IL273720A (enExample) |
| MA (1) | MA50369A (enExample) |
| MX (1) | MX2020003460A (enExample) |
| SG (1) | SG11202002697WA (enExample) |
| TW (1) | TW201934142A (enExample) |
| WO (1) | WO2019075188A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| CA3160151A1 (en) * | 2019-11-04 | 2021-05-14 | Seagen Inc. | Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection |
| KR102685068B1 (ko) * | 2020-03-16 | 2024-07-16 | 가부시키가이샤 만다무 | T 세포성 림프종의 지표의 검출 방법, 및 그 이용 |
| EP4149558A1 (en) * | 2020-05-12 | 2023-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas |
| KR20230023650A (ko) * | 2020-05-13 | 2023-02-17 | 씨젠 인크. | 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법 |
| CA3203777A1 (en) * | 2020-12-03 | 2022-06-09 | Seagen Inc. | Modulating the immune response using anti-cd30 antibody-drug conjugates |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| WO2023028537A2 (en) * | 2021-08-25 | 2023-03-02 | R.P. Scherer Technologies, Llc | Antibodies having humanized framework regions |
| CN118451108A (zh) | 2021-10-29 | 2024-08-06 | 思进公司 | 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法 |
| CA3245067A1 (en) * | 2022-02-28 | 2023-08-31 | Adc Therapeutics Sa | DOSAGE REGIMEN |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123536A1 (en) * | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
| WO2008025020A2 (en) * | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
| KR101641345B1 (ko) * | 2007-10-12 | 2016-07-20 | 시애틀 지네틱스, 인크. | 항체-약물 접합체를 이용한 병용 요법 |
| WO2010081004A1 (en) * | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| WO2015037000A1 (en) * | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| MX390955B (es) * | 2016-06-02 | 2025-03-19 | Seagen Inc | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma. |
| WO2018112032A1 (en) * | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
-
2018
- 2018-10-11 MA MA050369A patent/MA50369A/fr unknown
- 2018-10-11 BR BR112020007119-6A patent/BR112020007119A2/pt not_active Application Discontinuation
- 2018-10-11 MX MX2020003460A patent/MX2020003460A/es unknown
- 2018-10-11 CN CN201880079374.3A patent/CN111683677A/zh active Pending
- 2018-10-11 EP EP18865815.7A patent/EP3694544A4/en not_active Withdrawn
- 2018-10-11 KR KR1020207013530A patent/KR20200070317A/ko not_active Withdrawn
- 2018-10-11 SG SG11202002697WA patent/SG11202002697WA/en unknown
- 2018-10-11 WO PCT/US2018/055388 patent/WO2019075188A1/en not_active Ceased
- 2018-10-11 CN CN202410254365.0A patent/CN118356508A/zh active Pending
- 2018-10-11 JP JP2020520650A patent/JP2020536932A/ja active Pending
- 2018-10-11 AU AU2018348198A patent/AU2018348198A1/en not_active Abandoned
- 2018-10-11 US US16/755,091 patent/US20200239585A1/en not_active Abandoned
- 2018-10-11 CA CA3077729A patent/CA3077729A1/en active Pending
- 2018-10-12 TW TW107135971A patent/TW201934142A/zh unknown
-
2020
- 2020-03-31 IL IL273720A patent/IL273720A/en unknown
-
2022
- 2022-10-17 US US18/047,240 patent/US20230279133A1/en not_active Abandoned
-
2023
- 2023-11-10 JP JP2023191995A patent/JP2024016220A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11013803B2 (en) | Near infrared photoimmunotherapy (NIR-PIT) of suppressor cells to treat cancer | |
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| US20190290775A1 (en) | Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor | |
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2020508317A5 (enExample) | ||
| RU2016141576A (ru) | Конъюгаты "производное калихеамицина - носитель" | |
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2022512781A5 (enExample) | ||
| CA3117366A1 (en) | Methods for allogeneic hematopoietic stem cell transplantation | |
| PE20040519A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| WO2021024020A1 (en) | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer | |
| US20240307541A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| JP2020536932A (ja) | 抗体−薬物コンジュゲートを用いた免疫応答の調節 | |
| JP2021501776A5 (enExample) | ||
| JP2021535149A5 (enExample) | ||
| JP2021523158A5 (enExample) | ||
| JP2021523233A5 (enExample) | ||
| JP2019011317A (ja) | 溶血性レンサ球菌の菌体を含む製剤との併用療法 | |
| KR102912346B1 (ko) | 약학적 배합물 | |
| Atallah-Yunes et al. | Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma | |
| Gallotta et al. | NX-1607, a small molecule inhibitor of the CBL-B E3 ubiquitin ligase, promotes T and NK cell activation and enhances NK-mediated ADCC in a mouse lymphoma tumor model | |
| IL316538A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| JP2024521667A (ja) | 抗－ｃｄ２０５抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬 | |
| Wang et al. | OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab |